Metabolic Evaluation of Stone Disease

20
Metabolic Evaluation of Stone Disease Department of Urology Pediatric Unit

description

Metabolic Evaluation of Stone Diseases

Transcript of Metabolic Evaluation of Stone Disease

Page 1: Metabolic Evaluation of Stone Disease

Metabolic Evaluation of Stone Disease

Department of UrologyPediatric Unit

Page 2: Metabolic Evaluation of Stone Disease

Renal stone disease continues to be considerable medical problem, often causing significant patient morbidity.

Page 3: Metabolic Evaluation of Stone Disease

Main Stone Classification

Calcium Stones

Non-Calcium Stones

Page 4: Metabolic Evaluation of Stone Disease

Calcium Stones

Calcium Oxalate

Monohydrate

Calcium Oxalate

Dihydrate

Calcium- Phosphate

Stones

Page 5: Metabolic Evaluation of Stone Disease

Main Stone Classification

Calcium Stones

Non-Calcium Stones

Page 6: Metabolic Evaluation of Stone Disease

Non-Calcium Stones

Infecion Stones

Uric Acid Stones

Cystine Stones

Xanthine Stones

Urate Containing

Stones

Drug Induced Stones

Page 7: Metabolic Evaluation of Stone Disease

Types of Urolithiasis Based on Stone Composition(Dorit E. Zilberman, Michael N. Ferrandino,

and Glenn M. Preminger)

Table 1

Page 8: Metabolic Evaluation of Stone Disease

Stone Composition & Possible Clinical Associations

Table 2

• Stones with calcium components develop as a result of the greatest variety of metabolic disorders and often patients present with a combination of stone forming risk factors.

Calcium Stones

Page 9: Metabolic Evaluation of Stone Disease

Uric Acid Stones

• Patients with pure uric acid urolithiasis generally have a low urinary pH (<5.5) and are therefore defined as having gouty diathesis.

Infection Stones

• High urinary pH (>7.5) is associated with infection. Urea splitting organisms leads to an increase in the ammonia concentration, which promotes infection stone formation, which compose the majority of stag-horn calculi.

Page 10: Metabolic Evaluation of Stone Disease

Cystine-Based Stones

• Cystine urolithiasis is the result of an autosomal recessive trait, which disrupts the transepithelial transport of cystine, ornithine, lysine, and arginine. The concentration of cystine rises to levels above the saturation point, leading to precepitation of cystine crystals.

• Even though cystine stone formers all have definitive genetic disorders, they have been found to have a number of other metabolic risk factors, which can contribute to their stone formation

Page 11: Metabolic Evaluation of Stone Disease

Metabolic Evaluation of Stone Disease

Why?• The main goal of metabolic evaluation is to

prevent recurrent stone formation in high-risk stone producers, as well as to prevent further growth of any existing stones.

Page 12: Metabolic Evaluation of Stone Disease

Metabolic Evaluation of Stone Disease

Who?1. Patient with stone who wishes to undergo metabolic evaluation2. Single stone with risk factors: a. Family history b. Intestinal disease c. Chronic diarrhea d. UTI e. Gouty f. Osteoporosis g. Skeletal fractures3. Recurrent stone formers4. Children5. Controversial: uric acid/struvite/cystine stones

Page 13: Metabolic Evaluation of Stone Disease

When?• Many authors suggest that one should wait at

least 1 month after stone passage or stone removal, allowing the patient to return to their normal routine, otherwise the metabolic evluation may yield unhelpful information.

Metabolic Evaluation of Stone Disease

Page 14: Metabolic Evaluation of Stone Disease

How?• History & Examination• Stone Analysis• Serum Chemistry• Urine Culture• Urinalysis• 24 hour urine collection• Radiological Imaging

Metabolic Evaluation of Stone Disease

Page 15: Metabolic Evaluation of Stone Disease

Metabolic Work-up of Stone

Disease

• The basic metabolic evaluation begins with a thorough history and physical exam, (similar previous conditions or family history)

• Stone Analysis: For patients with less common stone compositions – cystine, pure struvite, and pure uric acid –treatment regimens could begin immediately.

• Patients with calcium phosphate stones are known to be at increased risk from renal tubular acidosis and primary hyperparathyroidism, while patients with calcium oxalate stone formation have a mixture of metabolic diagnoses.

Page 16: Metabolic Evaluation of Stone Disease

• Serum chemistry consists of basic metabolic panel (e.g., sodium, potassium, chloride, carbon dioxide, blood urea nitrogen, creatinine) as well as calcium and uric acid.

• Hypercalcemia may be indicative of hyperparathyroidism and would warrant further evaluation with a parathyroid hormone assay. The presence of hypokalemia and hyper-chloremia is strongly suggestive of metabolic acidosis

Metabolic Work-up of Stone

Disease

Page 17: Metabolic Evaluation of Stone Disease

• Urine Cultures positive for Klebsiella, Proteus, Pseudomonas, or other urea-splitting organisms may indicate the presence of struvite stone

Metabolic Work-up of Stone

Disease

• Urine Analysis with PH between 6.8 and 7.2 suggestive of RTA, a pH greater than 7.5 correlated with urinary tract infection whereas a pH less than 5.5 defines the diagnosis of gouty diathesis.

Page 18: Metabolic Evaluation of Stone Disease

Metabolic Work-up of Stone

Disease

• 24 hour collection of urine to measure: total volume, pH, calcium, phosphorus, oxalate, citrate, sodium, magnesium, potassium, uric acid, and sulfate.

• It is our routine to have the patient collect two 24 h urine samples on two different days (either consecutive or separate) with the patient on their “normal routine” (normal diet, fluid intake, medications, physical exercise, etc) .

Page 19: Metabolic Evaluation of Stone Disease

Metabolic Work-up of Stone

Disease

• Many Authors consider radiologic imaging as a part of the basic metabolic evaluation, as there are insights which can be gleaned from the different imaging techniques.

• For example, multiple researchers have reported the use of CT to ascertain stone composition based on measurement of Hounsfield units

Page 20: Metabolic Evaluation of Stone Disease

Thank You

Ahmad Al-Sabbagh - December 2011*